Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alferminogene tadenovec

Drug Profile

Alferminogene tadenovec

Alternative Names: Ad5-FGF4; AdFGF-4; AGT-MI; Angiogenic gene therapy; Cardionovo; FGF-4 angiogenic DNA - Taxus Cardium Pharmaceuticals; FGF-4 gene therapy; Fibroblast growth factor-4 gene therapy - Taxus Cardium Pharmaceuticals; Generx; Generx microvascular therapy; mdFGF-4; mdFGF-4 - Taxus Cardium Pharmaceuticals

Latest Information Update: 10 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardium Therapeutics
  • Developer Angionetics; Gene Biotherapeutics; Taxus Cardium Pharmaceuticals Group
  • Class Gene therapies; Growth factors; Ischaemic heart disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Coronary artery disease; Myocardial ischaemia
  • Discontinued Heart failure

Most Recent Events

  • 07 Feb 2017 Alferminogene tadenovec receives Fast Track designation for Coronary artery disease [Intracoronary,Infusion] in USA
  • 12 Sep 2016 The U.S. FDA Center for Biologics Evaluation and Research approves alferminogene tadenovec for the phase III AFFIRM study in Coronary artery disease and Myocardial ischaemia
  • 11 Jul 2016 Alferminogene tadenovec licensed to an affiliated entity of Huapont Life Sciences in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top